Skip to main content

Table 3 Observed (Obs) and expected (Exp) numbers of cancer cases and standardised incidence ratios (SIR) with 95% confidence intervals (CI) among male workers at the Kokkola cobalt plant during 1969–2013, by site and duration of employment. Only primary sites with ≥2 observed or expected cancer cases included

From: Cancer incidence among Finnish male cobalt production workers in 1969–2013: a cohort study

Primary site Employment >1 year Employment >5 years
Obs Exp SIR 95% CI Obs Exp SIR 95% CI
All sites 92 91.9 1.00 0.81–1.22 77 71.6 1.08 0.85–1.34
Tongue 3 0.41 7.39 1.52–21.6 3 0.30 10.0 2.06–29.2
Oesophagus 2 1.15 1.74 0.21–6.28 2 0.89 2.24 0.27–8.08
Stomach 7 3.47 2.01 0.81–4.15 5 2.73 1.83 0.59–4.26
Colon 4 4.36 0.92 0.25–2.34 4 3.46 1.16 0.32–2.96
Rectum, rectosigmoid 4 3.80 1.05 0.29–2.69 3 2.93 1.03 0.21–2.99
Pancreas 2 3.44 0.58 0.07–2.09 1 2.69 0.37 0.01–2.07
Larynx, epiglottis 2 0.81 2.45 0.30–8.86 2 0.65 3.09 0.37–11.2
Lung, trachea 6 12.0 0.50 0.18–1.08 5 9.55 0.52 0.17–1.22
Melanoma of the skin 1 3.29 0.30 0.01–1.69 1 2.53 0.39 0.01–2.20
Skin, non-melanoma 3 2.78 1.08 0.22–3.15 3 2.22 1.35 0.28–3.94
Basal cell carcinoma of the skin 18 19.2 0.94 0.56–1.48 12 15.1 0.80 0.41–1.38
Prostate 33 24.4 1.35 0.93–1.89 26 19.4 1.34 0.87–1.96
Kidney 2 3.81 0.52 0.06–1.89 2 3.00 0.67 0.08–2.40
Bladder and urinary tract 9 4.79 1.88 0.86–3.56 6 3.76 1.60 0.59–3.47
Brain, central nervous system 2 2.82 0.71 0.09–2.56 2 2.07 0.97 0.12–3.49
Thyroid gland 2 0.99 2.01 0.24–7.26 2 0.72 2.78 0.34–10.0
Non-Hodgkin lymphoma 3 4.44 0.68 0.14–1.97 3 3.42 0.88 0.18–2.56
Leukaemia 3 2.11 1.42 0.29–4.15 3 1.58 1.90 0.39–5.54